# Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

> **NCT03737994** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 10 (actual)

## Conditions studied

- Lung Non-Squamous Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **DRUG:** Alectinib
- **DRUG:** Brigatinib
- **DRUG:** Carboplatin
- **DRUG:** Ceritinib
- **DRUG:** Cisplatin
- **DRUG:** Crizotinib
- **DRUG:** Ensartinib
- **DRUG:** Lorlatinib
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT03737994
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-25
- **Primary completion:** 2021-07-21
- **Final completion:** 2026-03-17
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Inadequate accrual rate
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03737994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03737994, "Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03737994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*